March 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Abdul Mannan: Why Apixaban May Be the Safer Choice for Acute VTE

Abdul Mannan/LinkedIn

Mar 14, 2026, 15:11

Abdul Mannan: Why Apixaban May Be the Safer Choice for Acute VTE

Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:

“For years, we’ve been prescribing both apixaban and rivaroxaban for acute VTE as if they were identical twins.

They’re not.

The COBRRA trial just published in NEJM (Castellucci LA et al., 2026) is the first randomised head-to-head comparison of these two DOACs in acute symptomatic VTE.

And the results are clear.

Here’s what the data shows:

Clinically Relevant Bleeding: 3.3 percent with apixaban versus 7.1 percent with rivaroxaban
Major Bleeding: 0.4 percent versus 2.4 percent (RR 0.16 – that is not a small difference)
Recurrent VTE: 1.1 percent versus 1.0 percent (no meaningful difference)

Same protection. Less bleeding. That’s a win for patients.

This was a pragmatic, open-label, blinded-endpoint trial with 1:1 allocation across acute proximal DVT and PE.

Real-world design. Blinded outcome adjudication. Three months follow-up.

The limitation worth noting: it excluded active cancer, pregnancy, severe renal impairment, and extreme body weight.

So this applies to your standard acute VTE patient, not every patient.

But for that standard patient?

The choice just got easier.

Apixaban appears to be the safer DOAC for acute VTE treatment when bleeding risk matters. And bleeding risk always matters.

Does this change your practice?

Are you already defaulting to apixaban, or does your institution still treat them as equivalent?

Drop your thoughts below.”

Abdul Mannan: Why Apixaban May Be the Safer Choice for Acute VTE